Application number | Title of the application | Filing Date | Status |
---|
09/673715 | Treatment of generalized anxiety disorder with paroxetine | Feb 6, 2001 | Abandoned |
Array
(
[id] => 6886759
[patent_doc_number] => 20010020028
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2001-09-06
[patent_title] => 'Agents for treating neurodegenerative disorders'
[patent_app_type] => new
[patent_app_number] => 09/778662
[patent_app_country] => US
[patent_app_date] => 2001-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10090
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0020/20010020028.pdf
[firstpage_image] =>[orig_patent_app_number] => 09778662
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/778662 | Agents for treating neurodegenerative disorders | Feb 5, 2001 | Abandoned |
09/776751 | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men | Feb 5, 2001 | Abandoned |
60/331370 | 5-HT1A receptor subtype agonist | Jan 28, 2001 | Pending |
Array
(
[id] => 1601342
[patent_doc_number] => 06476078
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2002-11-05
[patent_title] => 'Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction'
[patent_app_type] => B2
[patent_app_number] => 09/770663
[patent_app_country] => US
[patent_app_date] => 2001-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18344
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/476/06476078.pdf
[firstpage_image] =>[orig_patent_app_number] => 09770663
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/770663 | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction | Jan 28, 2001 | Issued |
Array
(
[id] => 6899981
[patent_doc_number] => 20010009657
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2001-07-26
[patent_title] => 'Determining effects of external stimuli on the brain using PET'
[patent_app_type] => new
[patent_app_number] => 09/764013
[patent_app_country] => US
[patent_app_date] => 2001-01-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 6115
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0009/20010009657.pdf
[firstpage_image] =>[orig_patent_app_number] => 09764013
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/764013 | Determining effects of external stimuli on the brain using PET | Jan 16, 2001 | Abandoned |
Array
(
[id] => 1548724
[patent_doc_number] => 06346282
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2002-02-12
[patent_title] => 'Neuroprotective composition for the prevention and/or treatment of nervous and behavioural alterations due to anxiety states or depression, comprising acetyl-L-carnitine and hypericin'
[patent_app_type] => B1
[patent_app_number] => 09/719551
[patent_app_country] => US
[patent_app_date] => 2000-12-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3385
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/346/06346282.pdf
[firstpage_image] =>[orig_patent_app_number] => 09719551
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/719551 | Neuroprotective composition for the prevention and/or treatment of nervous and behavioural alterations due to anxiety states or depression, comprising acetyl-L-carnitine and hypericin | Dec 25, 2000 | Issued |
Array
(
[id] => 1602788
[patent_doc_number] => 06432967
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2002-08-13
[patent_title] => 'Enema and enterically-coated oral dosage forms of azathioprine'
[patent_app_type] => B1
[patent_app_number] => 09/819051
[patent_app_country] => US
[patent_app_date] => 2000-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4085
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/432/06432967.pdf
[firstpage_image] =>[orig_patent_app_number] => 09819051
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/819051 | Enema and enterically-coated oral dosage forms of azathioprine | Dec 20, 2000 | Issued |
Array
(
[id] => 1566667
[patent_doc_number] => 06376478
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2002-04-23
[patent_title] => 'Pharmaceutical compositions and methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors'
[patent_app_type] => B1
[patent_app_number] => 09/741169
[patent_app_country] => US
[patent_app_date] => 2000-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13939
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/376/06376478.pdf
[firstpage_image] =>[orig_patent_app_number] => 09741169
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/741169 | Pharmaceutical compositions and methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors | Dec 20, 2000 | Issued |
Array
(
[id] => 1566869
[patent_doc_number] => 06376508
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2002-04-23
[patent_title] => 'Treatments for spinal muscular atrophy'
[patent_app_type] => B1
[patent_app_number] => 09/735766
[patent_app_country] => US
[patent_app_date] => 2000-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 10848
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/376/06376508.pdf
[firstpage_image] =>[orig_patent_app_number] => 09735766
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/735766 | Treatments for spinal muscular atrophy | Dec 12, 2000 | Issued |
Array
(
[id] => 7636989
[patent_doc_number] => 06379666
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2002-04-30
[patent_title] => 'TNF inhibitors for the treatment of neurological, retinal and muscular disorders'
[patent_app_type] => B1
[patent_app_number] => 09/666068
[patent_app_country] => US
[patent_app_date] => 2000-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6154
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/379/06379666.pdf
[firstpage_image] =>[orig_patent_app_number] => 09666068
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/666068 | TNF inhibitors for the treatment of neurological, retinal and muscular disorders | Dec 10, 2000 | Issued |
Array
(
[id] => 6880463
[patent_doc_number] => 20010031750
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2001-10-18
[patent_title] => 'Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold'
[patent_app_type] => new
[patent_app_number] => 09/731876
[patent_app_country] => US
[patent_app_date] => 2000-12-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 8467
[patent_no_of_claims] => 46
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0031/20010031750.pdf
[firstpage_image] =>[orig_patent_app_number] => 09731876
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/731876 | Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold | Dec 7, 2000 | Issued |
09/719181 | Use of an NK-1 receptor antagonist for treating cognitive disorders | Dec 7, 2000 | Abandoned |
Array
(
[id] => 1356012
[patent_doc_number] => 06576636
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2003-06-10
[patent_title] => 'Method of treating a liver disorder with fatty acid-antiviral agent conjugates'
[patent_app_type] => B2
[patent_app_number] => 09/730450
[patent_app_country] => US
[patent_app_date] => 2000-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 27
[patent_no_of_words] => 16176
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/576/06576636.pdf
[firstpage_image] =>[orig_patent_app_number] => 09730450
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/730450 | Method of treating a liver disorder with fatty acid-antiviral agent conjugates | Dec 4, 2000 | Issued |
Array
(
[id] => 1561913
[patent_doc_number] => 06362226
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2002-03-26
[patent_title] => 'Modulation of in vivo glutamine and glycine levels in the treatment of autism'
[patent_app_type] => B1
[patent_app_number] => 09/729881
[patent_app_country] => US
[patent_app_date] => 2000-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5773
[patent_no_of_claims] => 35
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/362/06362226.pdf
[firstpage_image] =>[orig_patent_app_number] => 09729881
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/729881 | Modulation of in vivo glutamine and glycine levels in the treatment of autism | Dec 4, 2000 | Issued |
Array
(
[id] => 1441342
[patent_doc_number] => 06335372
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2002-01-01
[patent_title] => 'Treatment of obsessive compulsive disorder'
[patent_app_type] => B1
[patent_app_number] => 09/722263
[patent_app_country] => US
[patent_app_date] => 2000-11-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 806
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/335/06335372.pdf
[firstpage_image] =>[orig_patent_app_number] => 09722263
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/722263 | Treatment of obsessive compulsive disorder | Nov 27, 2000 | Issued |
Array
(
[id] => 1441337
[patent_doc_number] => 06335371
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2002-01-01
[patent_title] => 'Method for inducing cognition enhancement'
[patent_app_type] => B1
[patent_app_number] => 09/722262
[patent_app_country] => US
[patent_app_date] => 2000-11-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1278
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/335/06335371.pdf
[firstpage_image] =>[orig_patent_app_number] => 09722262
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/722262 | Method for inducing cognition enhancement | Nov 27, 2000 | Issued |
Array
(
[id] => 1462922
[patent_doc_number] => 06350768
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2002-02-26
[patent_title] => 'Combination of riluzole and of gabapentin and its use as a medicament'
[patent_app_type] => B1
[patent_app_number] => 09/718543
[patent_app_country] => US
[patent_app_date] => 2000-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2167
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/350/06350768.pdf
[firstpage_image] =>[orig_patent_app_number] => 09718543
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/718543 | Combination of riluzole and of gabapentin and its use as a medicament | Nov 21, 2000 | Issued |
Array
(
[id] => 1586465
[patent_doc_number] => 06359010
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2002-03-19
[patent_title] => 'Methods of treating anxiety and mood disorders with oleamide'
[patent_app_type] => B1
[patent_app_number] => 09/718639
[patent_app_country] => US
[patent_app_date] => 2000-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 3546
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/359/06359010.pdf
[firstpage_image] =>[orig_patent_app_number] => 09718639
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/718639 | Methods of treating anxiety and mood disorders with oleamide | Nov 21, 2000 | Issued |
Array
(
[id] => 4305163
[patent_doc_number] => 06326362
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 2001-12-04
[patent_title] => '(-)-phosphonorisperidone and (-)-sulforisperidone compositions and methods'
[patent_app_type] => 1
[patent_app_number] => 9/700621
[patent_app_country] => US
[patent_app_date] => 2000-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3362
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/326/06326362.pdf
[firstpage_image] =>[orig_patent_app_number] => 700621
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/700621 | (-)-phosphonorisperidone and (-)-sulforisperidone compositions and methods | Nov 16, 2000 | Issued |